Introduction
Non-Hodgkin lymphoma (NHL) is the most commonly diagnosed hematologic malignancy in the United States, 1 and the lifetime odds of developing NHL is 1 in 47 for men and 1 in 55 for women. 2 Given the remarkable rise in incidence of NHL over the last 50 years, it is clear that environmental factors must play a major role in the etiology of this cancer, although established risk factors to date account for only a relatively small fraction of the total number of cases. 3 There is also accumulating evidence from migrant and analytical epidemiology studies that genetic susceptibility plays a role in NHL etiology, 4 ,5 although to date no major gene has been identified. However, case-control studies have identified several promising candidate susceptibility genes supporting a polygenic model based on low-penetrance alleles in line with the common-variant, common-disease hypothesis. 6 For NHL, the most compelling hypothesis for increased cancer risk is immune dysfunction, and this risk may be influenced in part by variation in polymorphic genes that control immune function and regulation. Recent studies have shown that single nucleotide polymorphisms (SNPs) from candidate genes including TNFα and LTA; [7] [8] [9] several interleukin genes including IL4, IL5, IL6 and IL10; 8, 10, 11 and genes related to innate immunity including FCGR2A, 9 TLR4, 12 and CARD15 12 may be risk factors for NHL overall or for certain NHL subtypes.
We undertook a discovery exercise to identify additional genes related to immune function and inflammation and risk of NHL by using the Affymetrix Immune and Inflammation SNP panel that included 9,412 SNPs from 1,253 genes. SNP coverage included both non-synonymous (ns) SNPs (N=537) and tagSNPs derived from the HapMap. Our analyses focused on both a gene-level test using all of the SNPs, and for nsSNPs, a SNP-level test, as the latter SNPs are expected to have a higher prior probability of functional significance. The study was conducted using a clinic-based case-control study of 458 NHL patients and 484 frequency-matched controls, and was based at the Mayo Clinic in Rochester, Minnesota.
only.
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Methods

Study population
This study was reviewed and approved by the Human Subjects Institutional Review Board at the Mayo Clinic, and all participants provided written informed consent. All consecutive cases of histologically-confirmed lymphoma (Hodgkin lymphoma and non-Hodgkin lymphoma including CLL) aged 20 years and older and a resident of Minnesota, Iowa or Wisconsin at the time of diagnosis who were within 9 months of their initial diagnosis at presentation to Mayo Clinic Rochester from 9/1/02 forward were offered enrollment into the study. Patients were excluded if they had HIV infection, did not speak English or were unable to provide written informed consent. A Mayo hematopathologist reviewed all materials for each case to verify the diagnosis and to classify each case into the World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues. 13 This (Phase I) analysis included all patients enrolled into the study from 9/1/02 through 9/30/05. Of the 956 eligible patients identified during this time frame, 629 (66%) participated, 106 (11%) refused, 19 (2%) we were unable to contact, and 202 (24%) had their eligibility expire (i.e., after identification they did not consent within 9 months of diagnosis or after consent they did not complete data collection within 12 months of diagnosis). A majority of patients who had their eligibility expire were only seen once at Mayo for a second opinion and these patients were generally recruited through the mail rather than in person.
Clinic-based controls were randomly selected from Mayo Clinic Rochester patients aged 20 years and older who were a resident of Minnesota, Iowa or Wisconsin and were being seen for a pre-scheduled medical examination in the general medicine divisions of the Department of Medicine from 9/1/02 through 9/30/05. Patients were not eligible if they had a history of lymphoma or leukemia, had HIV infection or did not speak English. Controls were frequency matched to the case distribution on 5-year age group, sex, and county of residence (county groupings based on distance from Rochester and urban/rural status) using a computer program only.
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Data collection
Participants completed a risk-factor questionnaire that included data on demographics, ethnicity, family cancer history, medical history, and selected lifestyle factors, and they also provided a peripheral blood sample for serologic and genetic studies. DNA was extracted from samples using a Gentra Systems automated salting-out methodology (Gentra Inc., Minneapolis, MN). A total of 498 (79%) cases and 497 (87%) controls had an extracted DNA sample available for genotyping in November 2005. DNA samples were randomly assigned to one of twelve 96-well plates. We also randomly selected (without replacement) two samples that were duplicated across plates and another two samples that were duplicated within each plate, for a total of 1043 study samples (995 unique samples and 48 duplicates). In addition, 8 wells on each plate were left blank for additional quality control samples (N=96). The remaining wells were either blank (N=10) or had water only (N=3). All source DNA tubes were barcoded and wanded into the Biomek NX software system creating a virtual plate map of the robotically plated samples.
Genotyping and quality control
Genotyping was conducted at the Affymetrix facility in South San Francisco, CA, using the Molecular Inversion Probe (MIP) genotyping technology, 14 which has a robust genotype calling methodology. 15 The Hardy-Weinberg equilibrium (HWE) was evaluated among the control subjects for each SNP using a chi-square test (MAF≥0.05) or an exact test (MAF<0.05). Because of multiple testing, SNPs found to be significant at a HWE threshold of 0.0001 were removed from further analyses. This threshold is conservative, i.e., removing more SNPs than may be necessary; however, because not all SNPs were independent, a Bonferroni correction would be too liberal (i.e., removing fewer SNPs than necessary). This removed 65 SNPs, and of these SNPs, we observed no clustering of HWE failures. All but two of these SNPs were independent of each other. In summary, we had 7,670 SNPs (375 nsSNPs) for analysis.
Statistical analysis
The independent effects of the matching variables age (including its functional form), gender, and geographic region were examined in unconditional logistic regression models; geographic region was not significant (p>0.2) and therefore was dropped from further consideration. We used unconditional logistic regression analysis to examine associations between each SNP and the risk of NHL, adjusting for the effects of age and gender. The most prevalent homozygous genotype was used as the reference group. Each polymorphism was modeled individually as having a log-additive effect in the regression model, and odds ratios (OR) and 95% confidence intervals were estimated. Associations between haplotypes from each gene and the risk of NHL were calculated using a score test implemented in HAPLO.SCORE 16 To reduce the potential that population stratification impacted our results, all analyses were restricted to subjects whose self-reported race was White. Additionally, we tested our White subjects for potential population stratification by randomly selecting 1000 independent (r 2 <0.25)
SNPs from our study and running the program Structure. 19 We found no evidence for population structure in our data.
Results
There were 458 NHL cases and 484 controls in this analysis, and all were White. Cases and controls were well matched on age, sex, state of residence and education level (Table 1) .
Cases were more likely to report a family history of NHL (4.8%) compared to controls (2.9%).
The most common subtypes were CLL/SLL (N=126), follicular (N=113), and DLBCL (N=76).
After all exclusions, there were 7,670 SNPs available for analysis, and these SNPs were assigned to 1158 genes based on chromosomal position using build 36 of the human genome (dbSNP). The average number of SNPs per gene was 6.1, with a minimum of 1 SNP (in 318 genes) and a maximum of 136 SNPs for one gene. There were also a total of 375 nsSNPs only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From available for analysis, and these were assigned to 262 genes. Supplemental Table 1 reports all of the SNPs and their MAF among the controls. Table 2 reports the gene level results based on the logistic regression and haplotype analyses, ranked by p-value for all p≤0.001 from either analysis. We also report results for the individual SNPs within these genes. Based on the logistic regression analysis, the smallest pvalues were seen for CREB1 (p=0.0001) and FGG (p=0.0001). In CREB1, there were 5 SNPs with a p≤0.05, and the SNP with the smallest p-value (0.002) was rs2551919 with an ordinal OR Table 3 reports the results for the six nsSNPs ranked by the p-value from the ordinal (log additive) model with a p≤0.01. The smallest p-value was for ITGB3 (p=0.001), and the ordinal OR was 0.66 (95% CI 0.52-0.85). The tail strength for the nsSNP analysis (based on 375 pvalues) was 0.04 (-0.06 -0.14), suggesting that none of these results were significant after accounting for multiple testing. Table 3 also reports the amino acid change for the nsSNPs; all of these changes were predicted to be benign using the software Polyphen (genetics.bwh.harvard.edu/pph).
As a secondary analysis, we evaluated the gene level (Table 2 and Supplemental Table 2) and nsSNP (Table 3 ) associations for the three most common NHL subtypes in our dataset. 
Discussion
In a discovery exercise, we used a panel of genes related to immune function and inflammation to identify genetic risk factors for NHL. After exclusion of SNPs that did not meet our strict quality control or that had a MAF of less 0.01, we had data available for 7,670 SNPs assigned to 1,158 genes. We identified 9 genes and 6 nsSNPs (from 6 genes) of greatest interest based on our statistical criteria. These types of analyses are prone to false discovery due to the large number of statistical tests that are conducted, and while the signal from our gene level analysis suggested that we observed a 10% greater signal over chance, our nsSNP findings were consistent with a chance finding after accounting for the number of tests conducted. Ultimately, replication of genetic associations in independent studies or within a consortium such as InterLymph 8 is required, and the genes we identified are excellent candidates.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From This is the largest evaluation of genes involved in immunity and inflammation reported to date for NHL. While our findings must be considered preliminary and hypothesis-generating, we observed several patterns among the highest ranked genes that are supported by the limited existing literature on genetic susceptibility to NHL ( is predicted to be benign using Polyphen, further analysis in this gene rich area is warranted.
TLRs bridge the innate and adaptive immune systems, 27 and the nsSNP in TLR6 (rs5743815) that was associated with risk in this study has not previously been evaluated in NHL. Little is known about the functional consequences, if any, of this SNP, although the substitution (V427A) was predicted to be benign using Polyphen. While the MAF was low in cases (0.02) and controls (0.004), the association was strong for NHL overall (OR=5.20; 95% CI 1.77-15.3) and for each of the subtypes. A nsSNP from TLR2 (-16933T>A) has been reported to be associated with NHL overall and with follicular lymphoma in particular, 28 and a nsSNP in TLR4 (rs4986790; 1063A>G) was associated with DLBCL in one study, 12 although this was not observed in two other studies. 9, 28 Our data also suggest a role for genetic variation in signal transduction pathways, particularly related to TNF and TLR signaling. MAP3K5 belongs to the mitogen-activated protein kinases (MAPK) pathway, and it can be activated by TNFα through interactions with only.
For 33 and is a putative oncogene that has been implicated in several cancers including myeloid neoplasia and follicular and transformed NHL. 34 CREB is activated by TNF/TNFR1 signaling through a p38MAPK/MSK1 signaling pathway and through TLR signaling. 35, 36 Of note, the associations for MAP3K5, DUSP2, and CREB1 were not specific to any NHL subtype, suggesting these genes may play a more global role in lymphomagenesis.
Genes involved in lymphocyte trafficking and migration were also in our top hits. B3GNT3,
plays an important role in L-selectin biosynthesis 37 and SELPLG encodes a ligand for P-selectin (PSGL-1), which is important for tethering and rolling of leukocytes to endothelial cells and platelets 38 and also may activate ß 2 integrins in neutrophils. 39 Selectins appear to play an important role in tumor cell survival and metastasis, 40 and increased soluble P-selectin has been reported in breast and hematologic cancers. 41 Our final and perhaps most unexpected observation was that genes involved in the acutephase response and the coagulation-fibrinolytic system, specifically FGG and ITGB3, were associated with NHL risk. There is accumulating experimental evidence for a role of fibrin and fibrinogen degradation products in carcinogenesis by promoting invasive growth, angiogenesis, and metastasis. [42] [43] [44] ITGB3 codes for the beta subunit of the glycoprotein IIb/IIIa complex which mediates platelet aggregation by serving as a receptor for fibrinogen. The ITGB3 nsSNP rs5918 results in a substitution (Leu59Pro, also reported as Leu33Pro) that introduces a nick in the polypeptide chain, and this SNP leads to increased binding of fibrinogen to the IIb/IlIa complex, 45 increased platelet aggregation, 46 decreased bleeding time, 47 and increased signaling through ERK2 of the MAPK pathway. 48 In contrast to our results, this SNP has been associated only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From with risk of all cancer in a Danish cohort study (RR Pro/Pro =1.4, 95% CI 1.1-1.9). 49 In subsite analysis of the Danish cohort, risks were specific to ovarian and breast cancer and melanoma; results specific to NHL were not reported (there were only 26 cases). NHL patients are at increased risks for coagulation disorders, 43 and patients with venous thromboembolism have been found to have increased risk of NHL even more than two years after admission (SIR=1.4; 95% CI 1.2-1.6). SNPs, 30%). The large number of exclusions for low MAF was mainly due to the inclusion of SNPs from other ethnic populations in the SNP panel, which had little or no variation in our White population. Based on the restriction of our analysis to Whites and the use of the Structure program, our results are not likely to be confounded by population stratification. While this restriction increases the internal validity of the results, it does decrease the generalizability of the findings to other racial/ethnic groups. Our study was not population-based, but we have carefully designed our clinic-based study to adhere to basic epidemiologic principles of the case-control study design, and in particular our controls are derived from the same underlying population source that generated our cases and were not selected on basis of any particular medical history or other exposure (including genotype). We also restricted case ascertainment only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From Page 14 to the 3-state region surrounding Mayo Clinic Rochester in order to reduce referral bias that can occur with patients coming from farther distances. Of note, hospital-based and populationbased studies have reported similar allele and genotype frequencies among controls for a variety of metabolic genes. 51 In summary, our study provides additional evidence of the important role played by genes involved in the immune response in the etiology of NHL, particularly with respect to TNF and TLR pathways and MAPK signaling. Our study further suggests genes involved lymphocyte trafficking and migration and coagulation pathways may also play important roles. Beyond the need to replicate these genes, additional work will need to be conducted to identify the causative SNPs in the candidate genes (e.g., by fine mapping), the role of genes up and DUSP2 is a member of the dual specificity protein phosphatase subfamily, which negatively regulates members of the mitogen-activated protein (MAP) kinase superfamily (MAPK/ERK, SAPK/JNK, p38). DUSP2 is predominantly expressed in hematopoietic lineages. Reduction of DUSP2 transcription using small interfering RNA inhibits p53-mediated apoptosis, whereas overexpression of DUSP2 increases susceptibility to apoptosis and suppresses tumor formation. DUSP2 knock out mice show reduced cytokine production and are protected from inflammatory arthritis. 
